Terms: = Liver cancer AND PSA AND Treatment
185 results:
1. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
Chen Q; Sun Q; Zhang J; Li B; Feng Q; Liu J
PLoS One; 2024; 19(3):e0295090. PubMed ID: 38437209
[TBL] [Abstract] [Full Text] [Related]
2. Pre-treatment
Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
[TBL] [Abstract] [Full Text] [Related]
3. Correlation between pre-radical prostatectomy standardized SUVmax ratios detected on 68Ga-PSMA-I&T PET/CT and final histopathology outcomes: an in-depth analysis.
Arıkan MG; Soyluoğlu S; Korkmaz Ü; Taştekin E; Elboğa U; Arda E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(2):100-106. PubMed ID: 38331250
[TBL] [Abstract] [Full Text] [Related]
4. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Halabi S; Guo S; Park JJ; Nanus DM; George DJ; Antonarakis ES; Danila DC; Szmulewitz RZ; McDonnell DP; Norris JD; Lu C; Luo J; Armstrong AJ
Clin Cancer Res; 2024 Mar; 30(6):1152-1159. PubMed ID: 38236581
[TBL] [Abstract] [Full Text] [Related]
5. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract] [Full Text] [Related]
6. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
Lv J; Yu H; Yin H; Shi Y; Shi H
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
[TBL] [Abstract] [Full Text] [Related]
7. Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.
Matsuoka T; Sugiyama A; Miyawaki Y; Hidaka Y; Okuno Y; Sakai H; Tanaka H; Yoshikawa K; Fukui T; Mizuno K; Sumiyoshi T; Goto T; Inoue T; Akamatsu S; Kobayashi T; Nakamura E
Cancer Sci; 2024 Jan; 115(1):283-297. PubMed ID: 37923364
[TBL] [Abstract] [Full Text] [Related]
8. A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the treatment of Metastatic Castration-Resistant Prostate cancer.
Laccetti AL; Bodei L; O'Donoghue JA; Weber WA; Morris MJ
Clin Nucl Med; 2023 Nov; 48(11):937-944. PubMed ID: 37812518
[TBL] [Abstract] [Full Text] [Related]
9. STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J; Philippe C; Schlederer M; Atas E; Pecoraro M; Grund-Gröschke S; Li WJ; Tracz A; Heidegger I; Lagger S; Trachtová K; Oberhuber M; Heitzer E; Aksoy O; Neubauer HA; Wingelhofer B; Orlova A; Witzeneder N; Dillinger T; Redl E; Greiner G; D'Andrea D; Östman JR; Tangermann S; Hermanova I; Schäfer G; Sternberg F; Pohl EE; Sternberg C; Varady A; Horvath J; Stoiber D; Malcolm TI; Turner SD; Parkes EE; Hantusch B; Egger G; Rose-John S; Poli V; Jain S; Armstrong CWD; Hoermann G; Goffin V; Aberger F; Moriggl R; Carracedo A; McKinney C; Kennedy RD; Klocker H; Speicher MR; Tang DG; Moazzami AA; Heery DM; Hacker M; Kenner L
Mol Cancer; 2023 Aug; 22(1):133. PubMed ID: 37573301
[TBL] [Abstract] [Full Text] [Related]
10. Extended therapy with [
Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
[TBL] [Abstract] [Full Text] [Related]
11. Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis.
Andreozzi G; Lorenzoni V; Bargellini I; Cioni R; Turchetti G
Cardiovasc Intervent Radiol; 2023 Mar; 46(3):319-326. PubMed ID: 36599950
[TBL] [Abstract] [Full Text] [Related]
12. Construction and validation of web-based nomograms for detecting and prognosticating in prostate adenocarcinoma with bone metastasis.
Dong Q; Wu X; Gan W; Mok TN; Shen J; Zha Z; Chen J
Sci Rep; 2022 Nov; 12(1):18623. PubMed ID: 36329203
[TBL] [Abstract] [Full Text] [Related]
13. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS;
Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050
[TBL] [Abstract] [Full Text] [Related]
14. Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma.
Lin X; Shi Q; Yang XJ
Hum Pathol; 2022 Dec; 130():36-46. PubMed ID: 36244466
[TBL] [Abstract] [Full Text] [Related]
15. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
Guo Z; Lu X; Yang F; Qin L; Yang N; Wu J; Wang H
Eur J Med Res; 2022 Aug; 27(1):148. PubMed ID: 35953852
[TBL] [Abstract] [Full Text] [Related]
16. Cost-Effectiveness of Donafenib as First-Line treatment of Unresectable Hepatocellular Carcinoma in China.
Guan H; Wang C; Zhao Z; Han S
Adv Ther; 2022 Jul; 39(7):3334-3346. PubMed ID: 35644019
[TBL] [Abstract] [Full Text] [Related]
17. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China.
Meng R; Cao Y; Zhou T; Hu H; Qiu Y
Front Public Health; 2022; 10():794131. PubMed ID: 35433574
[TBL] [Abstract] [Full Text] [Related]
18. A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Brown LC; Halabi S; Somarelli JA; Humeniuk M; Wu Y; Oyekunle T; Howard L; Huang J; Anand M; Davies C; Patel P; Staats J; Weinhold KJ; Harrison MR; Zhang T; George DJ; Armstrong AJ
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):762-769. PubMed ID: 35292724
[TBL] [Abstract] [Full Text] [Related]
19. Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
Zhang T; Kephart J; Bronson E; Anand M; Daly C; Spasojevic I; Bakthavatsalam S; Franz K; Berg H; Karachaliou GS; James OG; Howard L; Halabi S; Harrison MR; Armstrong AJ; George DJ
Prostate; 2022 May; 82(7):858-866. PubMed ID: 35286730
[TBL] [Abstract] [Full Text] [Related]
20. Tumor-targeted delivery of honokiol via polysialic acid modified zein nanoparticles prevents breast cancer progression and metastasis.
Zhang Q; Li D; Guan S; Liu D; Wang J; Xing G; Yue L; Cai D
Int J Biol Macromol; 2022 Apr; 203():280-291. PubMed ID: 35093442
[TBL] [Abstract] [Full Text] [Related]
[Next]
